Test Catalog

Test Id : B2MC

Beta-2-Microglobulin (Beta-2-M), Spinal Fluid

Useful For
Suggests clinical disorders or settings where the test may be helpful

Evaluation of central nervous system inflammation and B-cell proliferative diseases

Method Name
A short description of the method used to perform the test

Nephelometry

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Beta-2-Microglobulin, CSF

Aliases
Lists additional common names for a test, as an aid in searching

B2M, (Beta-2 Microglobulin), CSF Test

Beta 2 Microglobulin, CSF Test

Specimen Type
Describes the specimen type validated for testing

CSF

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Container/Tube: Sterile vial

Specimen Volume: 1 mL

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory

0.5 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Gross hemolysis OK

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
CSF Refrigerated (preferred) 28 days
Frozen 28 days
Ambient 14 days

Useful For
Suggests clinical disorders or settings where the test may be helpful

Evaluation of central nervous system inflammation and B-cell proliferative diseases

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Beta-2-microglobulin (BETA-2-M) is a small membrane protein (11,800 Dalton) associated with the heavy chains of class I major histocompatibility complex proteins and is, therefore, on the surface of all nucleated cells. The small size allows BETA-2-M to pass through the glomerular membrane, but it is almost completely reabsorbed in the proximal tubules.

 

Increased BETA-2-M levels in the cerebrospinal fluid (CSF) have been shown to be of diagnostic use in non-Hodgkin lymphoma with central nervous system involvement. Elevated CSF:serum ratios seen in patients with aseptic meningo-encephalitis suggest the possibility of neurologic processes including those associated with HIV infection and acute lymphoblastic leukemia. BETA-2-M measurement in multiple sclerosis seems to be of indeterminate usefulness.

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

0.70-1.80 mcg/mL

Interpretation
Provides information to assist in interpretation of the test results

Elevations of cerebrospinal fluid beta-2-microgobulin levels may be seen in a number of diseases including malignancies, autoimmune disease, and neurological disorders.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

No significant cautionary statements

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Koch T, Lichtenfeld K, Wiernik P: Detection of central nervous system metastasis with cerebrospinal fluid beta 2 microglobulin. Cancer 1983;52:101-104

2. Mavligit G, Stuckey S, Fernando B, et al: Diagnosis of leukemia or lymphoma in the central nervous system by beta 2 microglobulin determination. N Engl J Med 1980;303:718-722

3. Jeffrey G, Frampton C, Legge H, et al: Cerebrospinal fluid beta 2 microglobulin levels in meningeal involvement by malignancy. Pathology 1990;22:20-23

4. Us O, Lolli F, Baig S, Link H: Intrathecal synthesis of beta 2 microglobulin in multiple sclerosis and aseptic meningo-encephalitis. Acta Neurol Scand 1989;80(6):598-602

5. Elovaara I, Livanainen M, Poitainen E, et al: CSF and serum beta 2 microglobulin in HIV infection related to neurological dysfunction. Acta Neurol Scand 1989;79(2):81-87

6. Dolan MF, Lucey DR, Hendrix CW, et al: Early markers of HIV infection and subclinical disease progression. Vaccine 1993;11(5):548-551

7. Brew BJ, Bhalla RB, Fleisher M, et al: Cerebrospinal fluid beta 2 microglobulin in patients infected with human immunodeficiency virus. Neurology 1989;39(6):830-834

8. Musto P, Tomasi P, Cascavilla N, et al: Significance and limits of cerebrospinal fluid beta 2 microglobulin measurement in course of acute lymphoblastic leukemia. Am J Hematol 1988;28(4):213-218

9. Lucey DR, McGuire SA, Clerici M, et al: Comparison of spinal fluid beta 2-microglobulin levels with CD4 + T cell count, in vitro T helper cell function, and spinal fluid IgG parameters in 163 neurologically normal adults infected with the human immunodeficiency virus type l. J Infect Dis 1991;163:971

10. Bjerrum L, Bach F, Zeeberg I: Increased level of cerebrospinal fluid beta 2 microglobulin is related to neurologic impairment in multiple sclerosis. Acta Neurol Scand 1988;78:72-75

Method Description
Describes how the test is performed and provides a method-specific reference

Concentrations of beta-2-microglobulin in cerebrospinal fluid are determined by nephelometry.(Instruction manual: Siemens Nephelometer II Operations. Siemens Inc, Newark, DE 05/2005)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday through Friday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

Same day/1 to 2 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

14 days

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

82232 

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports